Maze Therapeutics' Senior Vice President of Finance sold shares towards the end of January 2026, all while the company's stock had one of the best first-year performances of a biopharmaceutical ...

After Maze Therapeutics opted not to participate in the National Advertising Division’s (NAD’s) self-regulatory process for monitoring promotional claims, a case brought by competitor Vertex ...

Fierce 15 winner Maze Therapeutics just added $190 million to its fundraising pile in time to help its lead candidate, MZE001, make a clinical debut. Maze wrapped up the fundraising round on Monday.

Sanofi is offering up to $750 million in upfront cash and biobucks for Maze Therapeutics’ glycogen synthase 1 (GYS1) program, including a lead asset that’s recently completed a phase 1 trial for ...